Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma
Status:
Terminated
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
An attractive area of research regards immune manipulations to recover some of the patient's
immune response to his/her tumor, a strategy that has the advantages of being both natural
and potentially long-lasting.[1] We propose to combine immunotherapy with radiotherapy
directed to a metastatic site, to create a "hub" for in vivo immunization to the tumor, to
enable "tumor rejection" at the other metastatic sites. This "in vivo immunization" is
explored as a viable alternative to an individualized vaccine approach. Preclinical data
generated by us and others support a "proof of principle" clinical trial that may open the
field to an alternative use of radiotherapy in a novel partnership with cancer
immunotherapy.[2]
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health